Infliximab

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

COVID-19

Conditions

COVID-19

Trial Timeline

Jun 18, 2021 → Jul 1, 2023

NCT ID

NCT04922827

About Infliximab

Infliximab is a phase 2 stage product being developed by Celltrion for COVID-19. The current trial status is completed. This product is registered under clinical trial identifier NCT04922827. Target conditions include COVID-19.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04922827	Phase 2	Completed	Jun 18, 2021	Jul 1, 2023	COVID-19
NCT01571219	Phase 3	Completed	Mar 1, 2012	Jul 1, 2013	Rheumatoid Arthritis
NCT01571206	Phase 1	Completed	Mar 1, 2012	May 1, 2013	Ankylosing Spondylitis
NCT01220518	Phase 1	Completed	Oct 1, 2010	Jun 1, 2012	Ankylosing Spondylitis
NCT01217086	Phase 3	Completed	Oct 1, 2010	Jul 1, 2012	Rheumatoid Arthritis

Competing Products

20 competing products in COVID-19

See all competitors

Product	Company	Stage	Hype Score
Human COVID-19 immunoglobulin (pH4) for intravenous injection + Placebo	Sinopharm	Phase 2	51
Mavrilimumab + Placebos	Kiniksa Pharmaceuticals	Phase 2	47
Gimsilumab + Placebo	Roivant Sciences	Phase 2	49
Icosapent ethyl	Amarin Corporation	Phase 2	44
Bamlanivimab + Placebo + Etesevimab	Eli Lilly	Phase 3	77
CT-P63 and CT-P66 / Placebo	Celltrion	Phase 3	77
Enzalutamide Pill	Astellas Pharma	Phase 2	52
S-892216 + Placebo	Shionogi	Phase 2	52
S-892216 + Carbamazepine	Shionogi	Phase 1	33
FOY-305 + Placebo	Ono Pharmaceutical	Phase 3	77
Desidustat	Zydus Lifesciences	Phase 2	52
LY3819253 + Placebo	Eli Lilly	Phase 1	33
Bamlanivimab + Etesevimab + Placebo + VIR-7831 + Bebtelovimab	Eli Lilly	Phase 2	52
Bamlanivimab	Eli Lilly	Phase 2	52
LY3127804 + Placebo	Eli Lilly	Phase 2	52
Baricitinib + Placebo	Eli Lilly	Phase 3	77
Bamlanivimab	Eli Lilly	Pre-clinical	23
LY3819253 + Placebo + Remdesivir	Eli Lilly	Phase 3	77
LY3819253 + LY3832479 + LY3853113 + Placebo	Eli Lilly	Phase 2/3	65
Mesenchymal stem cell + Placebo	Rohto Pharmaceutical	Phase 2	52

Other Products from Celltrion

Azathioprine + PlaceboApproved

Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved

Infliximab + Infliximab + InfliximabApproved

Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved

Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved